Cargando…

Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer’s Disease from Other Neurological Disorders

Recently, the synaptic proteins neurogranin (Ng) and α-synuclein (α-Syn) have attracted scientific interest as potential biomarkers for synaptic dysfunction in neurodegenerative diseases. In this study, we measured the CSF Ng and α-Syn concentrations in patients affected by AD (n = 69), non-AD neuro...

Descripción completa

Detalles Bibliográficos
Autores principales: Piccoli, Tommaso, Blandino, Valeria, Maniscalco, Laura, Matranga, Domenica, Graziano, Fabiola, Guajana, Fabrizio, Agnello, Luisa, Lo Sasso, Bruna, Gambino, Caterina Maria, Giglio, Rosaria Vincenza, La Bella, Vincenzo, Ciaccio, Marcello, Colletti, Tiziana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501545/
https://www.ncbi.nlm.nih.gov/pubmed/36142742
http://dx.doi.org/10.3390/ijms231810831
_version_ 1784795501370015744
author Piccoli, Tommaso
Blandino, Valeria
Maniscalco, Laura
Matranga, Domenica
Graziano, Fabiola
Guajana, Fabrizio
Agnello, Luisa
Lo Sasso, Bruna
Gambino, Caterina Maria
Giglio, Rosaria Vincenza
La Bella, Vincenzo
Ciaccio, Marcello
Colletti, Tiziana
author_facet Piccoli, Tommaso
Blandino, Valeria
Maniscalco, Laura
Matranga, Domenica
Graziano, Fabiola
Guajana, Fabrizio
Agnello, Luisa
Lo Sasso, Bruna
Gambino, Caterina Maria
Giglio, Rosaria Vincenza
La Bella, Vincenzo
Ciaccio, Marcello
Colletti, Tiziana
author_sort Piccoli, Tommaso
collection PubMed
description Recently, the synaptic proteins neurogranin (Ng) and α-synuclein (α-Syn) have attracted scientific interest as potential biomarkers for synaptic dysfunction in neurodegenerative diseases. In this study, we measured the CSF Ng and α-Syn concentrations in patients affected by AD (n = 69), non-AD neurodegenerative disorders (n-AD = 50) and non-degenerative disorders (n-ND, n = 98). The concentrations of CSF Ng and α-Syn were significantly higher in AD than in n-AD and n-ND. Moreover, the Aβ42/Ng and Aβ42/α-Syn ratios showed statistically significant differences between groups and discriminated AD patients from n-AD patients, better than Ng or α-Syn alone. Regression analyses showed an association of higher Ng concentrations with MMSE < 24, pathological Aβ 42/40 ratios, pTau, tTau and the ApoEε4 genotype. Aβ 42/Ng was associated with MMSE < 24, an AD-related FDG-PET pattern, the ApoEε4 genotype, pathological Aβ 42 levels and Aβ 42/40 ratios, pTau, and tTau. Moreover, APO-Eε4 carriers showed higher Ng concentrations than non-carriers. Our results support the idea that the Aβ 42/Ng ratio is a reliable index of synaptic dysfunction/degeneration able to discriminate AD from other neurological conditions.
format Online
Article
Text
id pubmed-9501545
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95015452022-09-24 Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer’s Disease from Other Neurological Disorders Piccoli, Tommaso Blandino, Valeria Maniscalco, Laura Matranga, Domenica Graziano, Fabiola Guajana, Fabrizio Agnello, Luisa Lo Sasso, Bruna Gambino, Caterina Maria Giglio, Rosaria Vincenza La Bella, Vincenzo Ciaccio, Marcello Colletti, Tiziana Int J Mol Sci Article Recently, the synaptic proteins neurogranin (Ng) and α-synuclein (α-Syn) have attracted scientific interest as potential biomarkers for synaptic dysfunction in neurodegenerative diseases. In this study, we measured the CSF Ng and α-Syn concentrations in patients affected by AD (n = 69), non-AD neurodegenerative disorders (n-AD = 50) and non-degenerative disorders (n-ND, n = 98). The concentrations of CSF Ng and α-Syn were significantly higher in AD than in n-AD and n-ND. Moreover, the Aβ42/Ng and Aβ42/α-Syn ratios showed statistically significant differences between groups and discriminated AD patients from n-AD patients, better than Ng or α-Syn alone. Regression analyses showed an association of higher Ng concentrations with MMSE < 24, pathological Aβ 42/40 ratios, pTau, tTau and the ApoEε4 genotype. Aβ 42/Ng was associated with MMSE < 24, an AD-related FDG-PET pattern, the ApoEε4 genotype, pathological Aβ 42 levels and Aβ 42/40 ratios, pTau, and tTau. Moreover, APO-Eε4 carriers showed higher Ng concentrations than non-carriers. Our results support the idea that the Aβ 42/Ng ratio is a reliable index of synaptic dysfunction/degeneration able to discriminate AD from other neurological conditions. MDPI 2022-09-16 /pmc/articles/PMC9501545/ /pubmed/36142742 http://dx.doi.org/10.3390/ijms231810831 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Piccoli, Tommaso
Blandino, Valeria
Maniscalco, Laura
Matranga, Domenica
Graziano, Fabiola
Guajana, Fabrizio
Agnello, Luisa
Lo Sasso, Bruna
Gambino, Caterina Maria
Giglio, Rosaria Vincenza
La Bella, Vincenzo
Ciaccio, Marcello
Colletti, Tiziana
Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer’s Disease from Other Neurological Disorders
title Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer’s Disease from Other Neurological Disorders
title_full Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer’s Disease from Other Neurological Disorders
title_fullStr Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer’s Disease from Other Neurological Disorders
title_full_unstemmed Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer’s Disease from Other Neurological Disorders
title_short Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer’s Disease from Other Neurological Disorders
title_sort biomarkers related to synaptic dysfunction to discriminate alzheimer’s disease from other neurological disorders
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501545/
https://www.ncbi.nlm.nih.gov/pubmed/36142742
http://dx.doi.org/10.3390/ijms231810831
work_keys_str_mv AT piccolitommaso biomarkersrelatedtosynapticdysfunctiontodiscriminatealzheimersdiseasefromotherneurologicaldisorders
AT blandinovaleria biomarkersrelatedtosynapticdysfunctiontodiscriminatealzheimersdiseasefromotherneurologicaldisorders
AT maniscalcolaura biomarkersrelatedtosynapticdysfunctiontodiscriminatealzheimersdiseasefromotherneurologicaldisorders
AT matrangadomenica biomarkersrelatedtosynapticdysfunctiontodiscriminatealzheimersdiseasefromotherneurologicaldisorders
AT grazianofabiola biomarkersrelatedtosynapticdysfunctiontodiscriminatealzheimersdiseasefromotherneurologicaldisorders
AT guajanafabrizio biomarkersrelatedtosynapticdysfunctiontodiscriminatealzheimersdiseasefromotherneurologicaldisorders
AT agnelloluisa biomarkersrelatedtosynapticdysfunctiontodiscriminatealzheimersdiseasefromotherneurologicaldisorders
AT losassobruna biomarkersrelatedtosynapticdysfunctiontodiscriminatealzheimersdiseasefromotherneurologicaldisorders
AT gambinocaterinamaria biomarkersrelatedtosynapticdysfunctiontodiscriminatealzheimersdiseasefromotherneurologicaldisorders
AT gigliorosariavincenza biomarkersrelatedtosynapticdysfunctiontodiscriminatealzheimersdiseasefromotherneurologicaldisorders
AT labellavincenzo biomarkersrelatedtosynapticdysfunctiontodiscriminatealzheimersdiseasefromotherneurologicaldisorders
AT ciacciomarcello biomarkersrelatedtosynapticdysfunctiontodiscriminatealzheimersdiseasefromotherneurologicaldisorders
AT collettitiziana biomarkersrelatedtosynapticdysfunctiontodiscriminatealzheimersdiseasefromotherneurologicaldisorders